APO Research
Talk to an analyst

APO RESEARCH · REPORT

Allylamines Antifungal Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Allylamines Antifungal Drugs Market Outlook and Growth Opportunities 2026

23 December 2025203 pages

Choose your research edition.

Industry ResearchAllylamines Antifungal Drugs Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Allylamines Antifungal Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Allylamines Antifungal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Allylamines Antifungal Drugs Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Allylamines Antifungal Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Allylamines Antifungal Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Allylamines Antifungal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Allylamines Antifungal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Allylamines Antifungal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Allylamines Antifungal Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Allylamines Antifungal Drugs market include Chongqing Huapont Pharmaceutical, Yangtze River Pharmaceutical Group, Xiuzheng Pharmaceutical Group, Tongyao Pharmaceutical Group, Teva, Shandong Chenxin Pharmaceutical, Sandoz, Qilu Pharmaceutical and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Allylamines Antifungal Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Allylamines Antifungal Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Allylamines Antifungal Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Allylamines Antifungal Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Allylamines Antifungal Drugs Segment by Company

Chongqing Huapont Pharmaceutical

Yangtze River Pharmaceutical Group

Xiuzheng Pharmaceutical Group

Tongyao Pharmaceutical Group

Teva

Shandong Chenxin Pharmaceutical

Sandoz

Qilu Pharmaceutical

Novartis

Nanjing Chenggong Pharmaceutical

Mylan

Pfizer

Hunan Dinuo Pharmaceutical

Fuyuan Pharmaceutical

Bayer

Aobang Pharmaceutical

Gilead Sciences

Dr. Reddy's Laboratories

Cipla

Abbott Laboratories

Allylamines Antifungal Drugs Segment by Type

Terbinafine

Naftifine

Butenafine

Others

Allylamines Antifungal Drugs Segment by Application

Tinea Capitis

Dermatophytosis

Candidiasis

Tinea Versicolor

Others

Allylamines Antifungal Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Allylamines Antifungal Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Allylamines Antifungal Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Allylamines Antifungal Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Allylamines Antifungal Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Allylamines Antifungal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Allylamines Antifungal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Allylamines Antifungal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Allylamines Antifungal Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Allylamines Antifungal Drugs industry.

Chapter 3: Detailed analysis of Allylamines Antifungal Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Allylamines Antifungal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Allylamines Antifungal Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Allylamines Antifungal Drugs Industry Trends Table 2. Allylamines Antifungal Drugs Industry Drivers Table 3. Allylamines Antifungal Drugs Industry Opportunities and Challenges Table 4. Allylamines Antifungal Drugs Industry Restraints Table 5. Global Allylamines Antifungal Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Allylamines Antifungal Drugs Revenue Share by Company (2021-2026) Table 7. Global Allylamines Antifungal Drugs Sales Volume by Company (units) & (2021-2026) Table 8. Global Allylamines Antifungal Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Allylamines Antifungal Drugs Average Price (USD/unit) of Company (2021-2026) Table 10. Global Allylamines Antifungal Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Allylamines Antifungal Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Allylamines Antifungal Drugs Company, Product Type & Application Table 13. Global Allylamines Antifungal Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Allylamines Antifungal Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Terbinafine Table 18. Significant Companies of Naftifine Table 19. Significant Companies of Butenafine Table 20. Significant Companies of Others Table 21. Global Allylamines Antifungal Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 22. Global Allylamines Antifungal Drugs Sales Volume by Type (2021-2026) & (units) Table 23. Global Allylamines Antifungal Drugs Sales Volume by Type (2027-2032) & (units) Table 24. Global Allylamines Antifungal Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Allylamines Antifungal Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Allylamines Antifungal Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Allylamines Antifungal Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Allylamines Antifungal Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Allylamines Antifungal Drugs Sales Value Share by Type (2021-2026) Table 30. Global Allylamines Antifungal Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Tinea Capitis Table 32. Significant Companies of Dermatophytosis Table 33. Significant Companies of Candidiasis Table 34. Significant Companies of Tinea Versicolor Table 35. Significant Companies of Others Table 36. Global Allylamines Antifungal Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 37. Global Allylamines Antifungal Drugs Sales Volume by Application (2021-2026) & (units) Table 38. Global Allylamines Antifungal Drugs Sales Volume by Application (2027-2032) & (units) Table 39. Global Allylamines Antifungal Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Allylamines Antifungal Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Allylamines Antifungal Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Allylamines Antifungal Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Allylamines Antifungal Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Allylamines Antifungal Drugs Sales Value Share by Application (2021-2026) Table 45. Global Allylamines Antifungal Drugs Sales Value Share by Application (2027-2032) Table 46. Global Allylamines Antifungal Drugs Sales by Region: 2021 VS 2025 VS 2032 (units) Table 47. Global Allylamines Antifungal Drugs Sales by Region (2021-2026) & (units) Table 48. Global Allylamines Antifungal Drugs Sales Market Share by Region (2021-2026) Table 49. Global Allylamines Antifungal Drugs Sales by Region (2027-2032) & (units) Table 50. Global Allylamines Antifungal Drugs Sales Market Share by Region (2027-2032) Table 51. Global Allylamines Antifungal Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Allylamines Antifungal Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Allylamines Antifungal Drugs Sales Value Share by Region (2021-2026) Table 54. Global Allylamines Antifungal Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Allylamines Antifungal Drugs Sales Value Share by Region (2027-2032) Table 56. Global Allylamines Antifungal Drugs Market Average Price (USD/unit) by Region (2021-2026) Table 57. Global Allylamines Antifungal Drugs Market Average Price (USD/unit) by Region (2027-2032) Table 58. Global Allylamines Antifungal Drugs Sales by Country: 2021 VS 2025 VS 2032 (units) Table 59. Global Allylamines Antifungal Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Allylamines Antifungal Drugs Sales by Country (2021-2026) & (units) Table 61. Global Allylamines Antifungal Drugs Sales Market Share by Country (2021-2026) Table 62. Global Allylamines Antifungal Drugs Sales by Country (2027-2032) & (units) Table 63. Global Allylamines Antifungal Drugs Sales Market Share by Country (2027-2032) Table 64. Global Allylamines Antifungal Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Allylamines Antifungal Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Allylamines Antifungal Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Allylamines Antifungal Drugs Sales Value Market Share by Country (2027-2032) Table 68. Chongqing Huapont Pharmaceutical Company Information Table 69. Chongqing Huapont Pharmaceutical Business Overview Table 70. Chongqing Huapont Pharmaceutical Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Chongqing Huapont Pharmaceutical Allylamines Antifungal Drugs Product Portfolio Table 72. Chongqing Huapont Pharmaceutical Recent Development Table 73. Yangtze River Pharmaceutical Group Company Information Table 74. Yangtze River Pharmaceutical Group Business Overview Table 75. Yangtze River Pharmaceutical Group Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Yangtze River Pharmaceutical Group Allylamines Antifungal Drugs Product Portfolio Table 77. Yangtze River Pharmaceutical Group Recent Development Table 78. Xiuzheng Pharmaceutical Group Company Information Table 79. Xiuzheng Pharmaceutical Group Business Overview Table 80. Xiuzheng Pharmaceutical Group Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Xiuzheng Pharmaceutical Group Allylamines Antifungal Drugs Product Portfolio Table 82. Xiuzheng Pharmaceutical Group Recent Development Table 83. Tongyao Pharmaceutical Group Company Information Table 84. Tongyao Pharmaceutical Group Business Overview Table 85. Tongyao Pharmaceutical Group Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Tongyao Pharmaceutical Group Allylamines Antifungal Drugs Product Portfolio Table 87. Tongyao Pharmaceutical Group Recent Development Table 88. Teva Company Information Table 89. Teva Business Overview Table 90. Teva Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Teva Allylamines Antifungal Drugs Product Portfolio Table 92. Teva Recent Development Table 93. Shandong Chenxin Pharmaceutical Company Information Table 94. Shandong Chenxin Pharmaceutical Business Overview Table 95. Shandong Chenxin Pharmaceutical Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Shandong Chenxin Pharmaceutical Allylamines Antifungal Drugs Product Portfolio Table 97. Shandong Chenxin Pharmaceutical Recent Development Table 98. Sandoz Company Information Table 99. Sandoz Business Overview Table 100. Sandoz Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Sandoz Allylamines Antifungal Drugs Product Portfolio Table 102. Sandoz Recent Development Table 103. Qilu Pharmaceutical Company Information Table 104. Qilu Pharmaceutical Business Overview Table 105. Qilu Pharmaceutical Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Qilu Pharmaceutical Allylamines Antifungal Drugs Product Portfolio Table 107. Qilu Pharmaceutical Recent Development Table 108. Novartis Company Information Table 109. Novartis Business Overview Table 110. Novartis Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Novartis Allylamines Antifungal Drugs Product Portfolio Table 112. Novartis Recent Development Table 113. Nanjing Chenggong Pharmaceutical Company Information Table 114. Nanjing Chenggong Pharmaceutical Business Overview Table 115. Nanjing Chenggong Pharmaceutical Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Nanjing Chenggong Pharmaceutical Allylamines Antifungal Drugs Product Portfolio Table 117. Nanjing Chenggong Pharmaceutical Recent Development Table 118. Mylan Company Information Table 119. Mylan Business Overview Table 120. Mylan Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Mylan Allylamines Antifungal Drugs Product Portfolio Table 122. Mylan Recent Development Table 123. Pfizer Company Information Table 124. Pfizer Business Overview Table 125. Pfizer Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Pfizer Allylamines Antifungal Drugs Product Portfolio Table 127. Pfizer Recent Development Table 128. Hunan Dinuo Pharmaceutical Company Information Table 129. Hunan Dinuo Pharmaceutical Business Overview Table 130. Hunan Dinuo Pharmaceutical Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Hunan Dinuo Pharmaceutical Allylamines Antifungal Drugs Product Portfolio Table 132. Hunan Dinuo Pharmaceutical Recent Development Table 133. Fuyuan Pharmaceutical Company Information Table 134. Fuyuan Pharmaceutical Business Overview Table 135. Fuyuan Pharmaceutical Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Fuyuan Pharmaceutical Allylamines Antifungal Drugs Product Portfolio Table 137. Fuyuan Pharmaceutical Recent Development Table 138. Bayer Company Information Table 139. Bayer Business Overview Table 140. Bayer Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Bayer Allylamines Antifungal Drugs Product Portfolio Table 142. Bayer Recent Development Table 143. Aobang Pharmaceutical Company Information Table 144. Aobang Pharmaceutical Business Overview Table 145. Aobang Pharmaceutical Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Aobang Pharmaceutical Allylamines Antifungal Drugs Product Portfolio Table 147. Aobang Pharmaceutical Recent Development Table 148. Gilead Sciences Company Information Table 149. Gilead Sciences Business Overview Table 150. Gilead Sciences Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Gilead Sciences Allylamines Antifungal Drugs Product Portfolio Table 152. Gilead Sciences Recent Development Table 153. Dr. Reddy's Laboratories Company Information Table 154. Dr. Reddy's Laboratories Business Overview Table 155. Dr. Reddy's Laboratories Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Dr. Reddy's Laboratories Allylamines Antifungal Drugs Product Portfolio Table 157. Dr. Reddy's Laboratories Recent Development Table 158. Cipla Company Information Table 159. Cipla Business Overview Table 160. Cipla Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. Cipla Allylamines Antifungal Drugs Product Portfolio Table 162. Cipla Recent Development Table 163. Abbott Laboratories Company Information Table 164. Abbott Laboratories Business Overview Table 165. Abbott Laboratories Allylamines Antifungal Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. Abbott Laboratories Allylamines Antifungal Drugs Product Portfolio Table 167. Abbott Laboratories Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Allylamines Antifungal Drugs Distributors List Table 171. Allylamines Antifungal Drugs Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Allylamines Antifungal Drugs Product Image Figure 2. Global Allylamines Antifungal Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Allylamines Antifungal Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Allylamines Antifungal Drugs Sales (2021-2032) & (units) Figure 5. Global Allylamines Antifungal Drugs Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Allylamines Antifungal Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Terbinafine Image Figure 10. Naftifine Image Figure 11. Butenafine Image Figure 12. Others Image Figure 13. Global Allylamines Antifungal Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 14. Global Allylamines Antifungal Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Allylamines Antifungal Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Allylamines Antifungal Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Allylamines Antifungal Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Allylamines Antifungal Drugs Sales Value Share by Type (2021-2032) Figure 19. Tinea Capitis Image Figure 20. Dermatophytosis Image Figure 21. Candidiasis Image Figure 22. Tinea Versicolor Image Figure 23. Others Image Figure 24. Global Allylamines Antifungal Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 25. Global Allylamines Antifungal Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Allylamines Antifungal Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Allylamines Antifungal Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Allylamines Antifungal Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Allylamines Antifungal Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Allylamines Antifungal Drugs Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 31. Global Allylamines Antifungal Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Allylamines Antifungal Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Allylamines Antifungal Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Allylamines Antifungal Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Allylamines Antifungal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Allylamines Antifungal Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Allylamines Antifungal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Allylamines Antifungal Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Allylamines Antifungal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Allylamines Antifungal Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Allylamines Antifungal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Allylamines Antifungal Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Allylamines Antifungal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Allylamines Antifungal Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Allylamines Antifungal Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Terbinafine
  • Naftifine
  • Butenafine
  • Others
Applications
  • Tinea Capitis
  • Dermatophytosis
  • Candidiasis
  • Tinea Versicolor
  • Others
Companies covered
  • Chongqing Huapont Pharmaceutical
  • Yangtze River Pharmaceutical Group
  • Xiuzheng Pharmaceutical Group
  • Tongyao Pharmaceutical Group
  • Teva
  • Shandong Chenxin Pharmaceutical
  • Sandoz
  • Qilu Pharmaceutical
  • Novartis
  • Nanjing Chenggong Pharmaceutical
  • Mylan
  • Pfizer
  • Hunan Dinuo Pharmaceutical
  • Fuyuan Pharmaceutical
  • Bayer
  • Aobang Pharmaceutical
  • Gilead Sciences
  • Dr. Reddy's Laboratories
  • Cipla
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Allylamines Antifungal Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Allylamines Antifungal Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Allylamines Antifungal Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Allylamines Antifungal Drugs Market Dynamics
  1. 2.1 Allylamines Antifungal Drugs Industry Trends
  2. 2.2 Allylamines Antifungal Drugs Industry Drivers
  3. 2.3 Allylamines Antifungal Drugs Industry Opportunities and Challenges
  4. 2.4 Allylamines Antifungal Drugs Industry Restraints
3 Allylamines Antifungal Drugs Market by Company
  1. 3.1 Global Allylamines Antifungal Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Allylamines Antifungal Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Allylamines Antifungal Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Allylamines Antifungal Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Allylamines Antifungal Drugs Company Ranking (2024-2026)
  6. 3.6 Global Allylamines Antifungal Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Allylamines Antifungal Drugs Company Product Type and Application
  8. 3.8 Global Allylamines Antifungal Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Allylamines Antifungal Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Allylamines Antifungal Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Allylamines Antifungal Drugs Market by Type
  1. 4.1 Allylamines Antifungal Drugs Type Introduction
  2. 4.1.1 Terbinafine
  3. 4.1.2 Naftifine
  4. 4.1.3 Butenafine
  5. 4.1.4 Others
  6. 4.2 Global Allylamines Antifungal Drugs Sales Volume by Type
  7. 4.2.1 Global Allylamines Antifungal Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Allylamines Antifungal Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Allylamines Antifungal Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Allylamines Antifungal Drugs Sales Value by Type
  11. 4.3.1 Global Allylamines Antifungal Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Allylamines Antifungal Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Allylamines Antifungal Drugs Sales Value Share by Type (2021-2032)
5 Allylamines Antifungal Drugs Market by Application
  1. 5.1 Allylamines Antifungal Drugs Application Introduction
  2. 5.1.1 Tinea Capitis
  3. 5.1.2 Dermatophytosis
  4. 5.1.3 Candidiasis
  5. 5.1.4 Tinea Versicolor
  6. 5.1.5 Others
  7. 5.2 Global Allylamines Antifungal Drugs Sales Volume by Application
  8. 5.2.1 Global Allylamines Antifungal Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Allylamines Antifungal Drugs Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Allylamines Antifungal Drugs Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Allylamines Antifungal Drugs Sales Value by Application
  12. 5.3.1 Global Allylamines Antifungal Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Allylamines Antifungal Drugs Sales Value by Application (2021-2032)
  14. 5.3.3 Global Allylamines Antifungal Drugs Sales Value Share by Application (2021-2032)
6 Allylamines Antifungal Drugs Regional Sales and Value Analysis
  1. 6.1 Global Allylamines Antifungal Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Allylamines Antifungal Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Allylamines Antifungal Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Allylamines Antifungal Drugs Sales by Region (2027-2032)
  5. 6.3 Global Allylamines Antifungal Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Allylamines Antifungal Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Allylamines Antifungal Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Allylamines Antifungal Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Allylamines Antifungal Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Allylamines Antifungal Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Allylamines Antifungal Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Allylamines Antifungal Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Allylamines Antifungal Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Allylamines Antifungal Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Allylamines Antifungal Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Allylamines Antifungal Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Allylamines Antifungal Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Allylamines Antifungal Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Allylamines Antifungal Drugs Sales Value Share by Country, 2025 VS 2032
7 Allylamines Antifungal Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Allylamines Antifungal Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Allylamines Antifungal Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Allylamines Antifungal Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Allylamines Antifungal Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Allylamines Antifungal Drugs Sales by Country (2027-2032)
  6. 7.4 Global Allylamines Antifungal Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Allylamines Antifungal Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Allylamines Antifungal Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Allylamines Antifungal Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Allylamines Antifungal Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Allylamines Antifungal Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing Huapont Pharmaceutical
  2. 8.1.1 Chongqing Huapont Pharmaceutical Company Information
  3. 8.1.2 Chongqing Huapont Pharmaceutical Business Overview
  4. 8.1.3 Chongqing Huapont Pharmaceutical Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing Huapont Pharmaceutical Allylamines Antifungal Drugs Product Portfolio
  6. 8.1.5 Chongqing Huapont Pharmaceutical Recent Developments
  7. 8.2 Yangtze River Pharmaceutical Group
  8. 8.2.1 Yangtze River Pharmaceutical Group Company Information
  9. 8.2.2 Yangtze River Pharmaceutical Group Business Overview
  10. 8.2.3 Yangtze River Pharmaceutical Group Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yangtze River Pharmaceutical Group Allylamines Antifungal Drugs Product Portfolio
  12. 8.2.5 Yangtze River Pharmaceutical Group Recent Developments
  13. 8.3 Xiuzheng Pharmaceutical Group
  14. 8.3.1 Xiuzheng Pharmaceutical Group Company Information
  15. 8.3.2 Xiuzheng Pharmaceutical Group Business Overview
  16. 8.3.3 Xiuzheng Pharmaceutical Group Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Xiuzheng Pharmaceutical Group Allylamines Antifungal Drugs Product Portfolio
  18. 8.3.5 Xiuzheng Pharmaceutical Group Recent Developments
  19. 8.4 Tongyao Pharmaceutical Group
  20. 8.4.1 Tongyao Pharmaceutical Group Company Information
  21. 8.4.2 Tongyao Pharmaceutical Group Business Overview
  22. 8.4.3 Tongyao Pharmaceutical Group Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Tongyao Pharmaceutical Group Allylamines Antifungal Drugs Product Portfolio
  24. 8.4.5 Tongyao Pharmaceutical Group Recent Developments
  25. 8.5 Teva
  26. 8.5.1 Teva Company Information
  27. 8.5.2 Teva Business Overview
  28. 8.5.3 Teva Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Teva Allylamines Antifungal Drugs Product Portfolio
  30. 8.5.5 Teva Recent Developments
  31. 8.6 Shandong Chenxin Pharmaceutical
  32. 8.6.1 Shandong Chenxin Pharmaceutical Company Information
  33. 8.6.2 Shandong Chenxin Pharmaceutical Business Overview
  34. 8.6.3 Shandong Chenxin Pharmaceutical Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Shandong Chenxin Pharmaceutical Allylamines Antifungal Drugs Product Portfolio
  36. 8.6.5 Shandong Chenxin Pharmaceutical Recent Developments
  37. 8.7 Sandoz
  38. 8.7.1 Sandoz Company Information
  39. 8.7.2 Sandoz Business Overview
  40. 8.7.3 Sandoz Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sandoz Allylamines Antifungal Drugs Product Portfolio
  42. 8.7.5 Sandoz Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Allylamines Antifungal Drugs Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Allylamines Antifungal Drugs Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Nanjing Chenggong Pharmaceutical
  56. 8.10.1 Nanjing Chenggong Pharmaceutical Company Information
  57. 8.10.2 Nanjing Chenggong Pharmaceutical Business Overview
  58. 8.10.3 Nanjing Chenggong Pharmaceutical Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Nanjing Chenggong Pharmaceutical Allylamines Antifungal Drugs Product Portfolio
  60. 8.10.5 Nanjing Chenggong Pharmaceutical Recent Developments
  61. 8.11 Mylan
  62. 8.11.1 Mylan Company Information
  63. 8.11.2 Mylan Business Overview
  64. 8.11.3 Mylan Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Mylan Allylamines Antifungal Drugs Product Portfolio
  66. 8.11.5 Mylan Recent Developments
  67. 8.12 Pfizer
  68. 8.12.1 Pfizer Company Information
  69. 8.12.2 Pfizer Business Overview
  70. 8.12.3 Pfizer Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Pfizer Allylamines Antifungal Drugs Product Portfolio
  72. 8.12.5 Pfizer Recent Developments
  73. 8.13 Hunan Dinuo Pharmaceutical
  74. 8.13.1 Hunan Dinuo Pharmaceutical Company Information
  75. 8.13.2 Hunan Dinuo Pharmaceutical Business Overview
  76. 8.13.3 Hunan Dinuo Pharmaceutical Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hunan Dinuo Pharmaceutical Allylamines Antifungal Drugs Product Portfolio
  78. 8.13.5 Hunan Dinuo Pharmaceutical Recent Developments
  79. 8.14 Fuyuan Pharmaceutical
  80. 8.14.1 Fuyuan Pharmaceutical Company Information
  81. 8.14.2 Fuyuan Pharmaceutical Business Overview
  82. 8.14.3 Fuyuan Pharmaceutical Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Fuyuan Pharmaceutical Allylamines Antifungal Drugs Product Portfolio
  84. 8.14.5 Fuyuan Pharmaceutical Recent Developments
  85. 8.15 Bayer
  86. 8.15.1 Bayer Company Information
  87. 8.15.2 Bayer Business Overview
  88. 8.15.3 Bayer Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Bayer Allylamines Antifungal Drugs Product Portfolio
  90. 8.15.5 Bayer Recent Developments
  91. 8.16 Aobang Pharmaceutical
  92. 8.16.1 Aobang Pharmaceutical Company Information
  93. 8.16.2 Aobang Pharmaceutical Business Overview
  94. 8.16.3 Aobang Pharmaceutical Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Aobang Pharmaceutical Allylamines Antifungal Drugs Product Portfolio
  96. 8.16.5 Aobang Pharmaceutical Recent Developments
  97. 8.17 Gilead Sciences
  98. 8.17.1 Gilead Sciences Company Information
  99. 8.17.2 Gilead Sciences Business Overview
  100. 8.17.3 Gilead Sciences Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Gilead Sciences Allylamines Antifungal Drugs Product Portfolio
  102. 8.17.5 Gilead Sciences Recent Developments
  103. 8.18 Dr. Reddy's Laboratories
  104. 8.18.1 Dr. Reddy's Laboratories Company Information
  105. 8.18.2 Dr. Reddy's Laboratories Business Overview
  106. 8.18.3 Dr. Reddy's Laboratories Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Dr. Reddy's Laboratories Allylamines Antifungal Drugs Product Portfolio
  108. 8.18.5 Dr. Reddy's Laboratories Recent Developments
  109. 8.19 Cipla
  110. 8.19.1 Cipla Company Information
  111. 8.19.2 Cipla Business Overview
  112. 8.19.3 Cipla Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Cipla Allylamines Antifungal Drugs Product Portfolio
  114. 8.19.5 Cipla Recent Developments
  115. 8.20 Abbott Laboratories
  116. 8.20.1 Abbott Laboratories Company Information
  117. 8.20.2 Abbott Laboratories Business Overview
  118. 8.20.3 Abbott Laboratories Allylamines Antifungal Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Abbott Laboratories Allylamines Antifungal Drugs Product Portfolio
  120. 8.20.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Allylamines Antifungal Drugs Value Chain Analysis
  2. 9.1.1 Allylamines Antifungal Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Allylamines Antifungal Drugs Sales Mode & Process
  6. 9.2 Allylamines Antifungal Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Allylamines Antifungal Drugs Distributors
  9. 9.2.3 Allylamines Antifungal Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst